GlassScriptPhysician profile
Dinesh Kapur
NPI 1538144522
$200,519.08
in general payments reported to CMS, 2019-2025
76 companies · $9,651 in 2025
The $9,651 reported for 2025 was more than what 88% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97K · 2020: $8,367 · 2021: $10K · 2022: $29K · 2023: $11K · 2024: $36K · 2025: $9,651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Consulting Fee: $17K · Food and Beverage: $11K · Travel and Lodging: $4,384 · Education: $620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,046.00 |
| Consulting Fee | $16,890.00 |
| Food and Beverage | $11,010.36 |
| Travel and Lodging | $4,383.71 |
| Education | $620.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $116,329.00 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Genentech USA, INC. | $43,357.02 | 2019-2025 | Tecentriq, Polivy, Lunsumio |
| Pharmacosmos Therapeutics INC. | $11,264.95 | 2022 | |
| Genzyme Corporation | $8,042.51 | 2019-2025 | |
| Epizyme, INC. | $3,559.43 | 2020-2022 | |
| Celgene Corporation | $1,724.05 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Karyopharm Therapeutics INC. | $1,669.42 | 2020-2025 | Xpovio |
| Astrazeneca Pharmaceuticals LP | $1,072.01 | 2019-2025 | Enhertu, Calquence, Imfinzi |
| Pfizer INC. | $1,030.76 | 2019-2025 | |
| Astellas Pharma US INC | $1,017.98 | 2019-2025 | Padcev, Xospata, Xtandi |
| Janssen Biotech, INC. | $1,004.37 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Novartis Pharmaceuticals Corporation | $954.74 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $769.39 | 2022-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Merck Sharp & Dohme LLC | $700.05 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $678.03 | 2019-2025 |
Show all 76 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $661.43 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Incyte Corporation | $457.08 | 2019-2024 | Jakafi, Monjuvi, Pemazyre |
| Gilead Sciences, INC. | $406.35 | 2021-2025 | Trodelvy |
| Exelixis INC. | $337.13 | 2019-2025 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $317.19 | 2022-2025 | Ninlaro, Fruzaqla, Iclusig |
| Abbvie INC. | $300.25 | 2020-2025 | |
| Seagen INC. | $297.72 | 2019-2023 | Adcetris, Tukysa |
| Eisai INC. | $293.27 | 2019-2025 | |
| Mirati Therapeutics, INC. | $281.18 | 2023-2024 | Krazati |
| Glaxosmithkline, LLC. | $272.96 | 2020-2025 | Ojjaara, Blenrep, Zejula |
| Janssen Pharmaceuticals, INC | $231.81 | 2019-2024 | Xarelto |
| Array Biopharma INC | $216.08 | 2021-2025 | Braftovi, Mektovi, Tukysa |
| Regeneron Healthcare Solutions, INC. | $215.77 | 2021-2025 | Libtayo |
| Adc Therapeutics America, INC. | $214.75 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $166.83 | 2020-2023 | Imbruvica |
| Beone Medicines USA, INC. | $154.78 | 2025 | Brukinsa, Tevimbra |
| Ipsen Biopharmaceuticals, INC | $151.42 | 2020-2022 | |
| Sobi, INC | $149.95 | 2023-2025 | |
| Daiichi Sankyo INC. | $139.13 | 2020-2025 | Enhertu, Injectafer |
| Alexion Pharmaceuticals, INC. | $126.20 | 2020-2025 | Ultomiris |
| Emd Serono, INC. | $122.63 | 2020-2025 | Bavencio |
| Jazz Pharmaceuticals INC. | $114.25 | 2019-2025 | |
| Amgen INC. | $114.19 | 2019-2023 | Vectibix, Xgeva, Nplate |
| Blueprint Medicines Corporation | $111.46 | 2020-2024 | Ayvakit |
| Geron Corporation | $97.09 | 2024-2025 | Rytelo |
| Pharmaessentia USA Corporation | $95.95 | 2022-2024 | Besremi |
| Sumitomo Pharma America, INC. | $93.84 | 2023-2025 | Orgovyx |
| Taiho Oncology, INC. | $81.82 | 2021-2025 | |
| Agios Pharmaceuticals, INC. | $78.51 | 2025 | Pyrukynd |
| Kite Pharma, INC. | $76.76 | 2020-2025 | Yescarta |
| Verastem, INC. | $72.17 | 2019-2025 | Avmapki Fakzynja Co-Pack |
| Coherus Oncology, INC. | $68.44 | 2020-2025 | Loqtorzi |
| Stemline Therapeutics INC. | $64.76 | 2023-2024 | Orserdu, Elzonris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.75 | 2019-2023 | Gilotrif |
| Genmab U.S., INC. | $59.56 | 2022-2024 | Epkinly |
| Acrotech Biopharma INC. | $57.56 | 2024-2025 | Beleodaq |
| Aveo Pharmaceuticals, INC. | $54.10 | 2023-2024 | Fotivda |
| Myovant Sciences INC. | $46.37 | 2021 | |
| Servier Pharmaceuticals LLC | $45.95 | 2025 | |
| Tesaro, INC. | $44.00 | 2019 | |
| Puma Biotechnology, INC. | $34.57 | 2019 | |
| Beigene USA, INC. | $29.88 | 2021-2023 | Brukinsa |
| Advanced Accelerator Applications | $24.97 | 2019 | |
| Sirtex Medical INC | $24.64 | 2022-2023 | Sir-Spheres Microspheres |
| Tg Therapeutics, INC. | $21.46 | 2021 | |
| Cti Biopharma Corp. | $19.84 | 2023 | Vonjo |
| Azurity Pharmaceuticals, INC. | $19.02 | 2025 | Danziten |
| Recordati_rare_diseases_inc. | $18.74 | 2025 | Enjaymo |
| Foundation Medicine, INC. | $18.58 | 2022 | |
| Heron Therapeutics, INC. | $16.92 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $16.80 | 2019 | |
| Mylan Institutional INC. | $16.10 | 2020 | |
| G1 Therapeutics, INC. | $15.93 | 2022 | |
| Iovance Biotherapeutics, INC. | $15.84 | 2025 | Amtagvi |
| Alnylam Pharmaceuticals INC. | $15.56 | 2023 | Givlaari |
| Myriad Genetic Laboratories, INC. | $15.48 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $15.14 | 2025 | Akynzeo |
| Clovis Oncology, INC. | $15.06 | 2019 | |
| Morphosys, US INC. | $14.50 | 2023 | Monjuvi |
| Tersera Therapeutics LLC | $13.59 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dinesh Kapur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.